Spyre Therapeutics, Inc. SEC filings SYRE
Spyre Therapeutics, Inc. has 823 filings in SEC EDGAR's recent list, going back to Mar 24, 2015. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 10, 2026 | — |
| DEF 14A | Proxy statement | Apr 10, 2026 | May 27, 2026 |
| DEFA14A | Additional proxy material | Apr 14, 2025 | — |
| DEF 14A | Proxy statement | Apr 14, 2025 | May 29, 2025 |
| DEF 14A | Proxy statement | Apr 1, 2024 | May 13, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 20, 2024 | May 13, 2024 |
| DEF 14A | Proxy statement | Oct 27, 2023 | Nov 21, 2023 |
| PRE 14A | Preliminary proxy statement | Aug 8, 2023 | Aug 7, 2023 |
| DEFA14A | Additional proxy material | May 19, 2023 | — |
| DEF 14A | Proxy statement | Apr 17, 2023 | Jun 6, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2023 | Jun 6, 2023 |
| DEF 14A | Proxy statement | Apr 21, 2022 | Jun 7, 2022 |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 8, 2021 |
| DEFA14A | Additional proxy material | May 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 8, 2020 |
| DEF 14A | Proxy statement | Apr 22, 2019 | Jun 7, 2019 |
| DEF 14A | Proxy statement | Sep 6, 2018 | Oct 8, 2018 |
| DEF 14A | Proxy statement | Apr 16, 2018 | Jun 7, 2018 |
| DEF 14A | Proxy statement | Apr 21, 2017 | Jun 7, 2017 |
Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1636282
- Former names
- Aeglea BioTherapeutics, Inc. (until Nov 24, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.